Did you know? You can suggest edits to improve this peptide information.
Overview
What is Omberacetam (Noopept)?
Omberacetam (also known as Noopept or GVS-111) is a synthetic nootropic dipeptide (N-phenylacetyl-L-prolylglycine ethyl ester) developed in Russia in 1996 for its potent cognitive-enhancing and neuroprotective properties. While structurally distinct from racetams, it's considered part of the nootropic family and functions as a prodrug that converts to the active metabolite cycloprolylglycine (CPG). Research indicates it may enhance memory, learning, and neuroplasticity through BDNF/NGF upregulation and glutamatergic modulation at doses 1000x lower than piracetam.
Key Benefits
Primary administration route, rapid oral bioavailability, convenient dosing, well-studied in clinical trials, peak absorption within 7 minutes
Mechanism of Action
Rapidly absorbed orally and converted to active metabolite cycloprolylglycine (CPG) which modulates AMPA/NMDA glutamate receptors and enhances cholinergic neurotransmission
Research Indications
Memory Enhancement
Improved memory consolidation and retrieval through enhanced synaptic plasticity and neurotrophic factor expression
Learning Acceleration
Faster acquisition of new information via AMPA receptor modulation and enhanced long-term potentiation
Focus and Concentration
Sustained attention improvements through acetylcholine sensitization and glutamatergic enhancement
Research Protocols
Disclaimer
These are commonly discussed research protocols and not medical advice. Consult a healthcare provider before use.
Timing
Morning and early afternoon dosing maximizes cognitive benefits while avoiding sleep disruption
Peptide Interactions
How to Reconstitute
Important
Always use bacteriostatic water (BAC). Sterile technique is essential.
Omberacetam is typically supplied as tablets (10mg), capsules, or powder form
For powder: Use precision scale capable of measuring milligrams accurately
Sublingual administration may enhance absorption - hold under tongue 30-60 seconds
Can be taken with or without food, though empty stomach may increase absorption speed
Consider pairing with a choline source (Alpha-GPC 300mg or CDP-Choline 250mg) to prevent headaches
Store in cool, dry place away from direct sunlight and moisture
Quality Indicators
White crystalline powder
Omberacetam should be white to off-white crystalline powder without discoloration
Third-party testing
Certificate of analysis showing purity ≥98% with HPLC verification
Proper packaging
Sealed containers protected from moisture with desiccant packets
Accurate dosing
Tablets/capsules should contain stated amount (typically 10mg per unit)
Headache potential
May cause headaches if taken without adequate choline - supplement accordingly
Discoloration or clumping
Yellow discoloration or excessive clumping may indicate degradation or contamination
What to Expect
- Days 1-3: Subtle cognitive clarity and mild focus enhancement; possible initial headache if not using choline
- Week 1: Noticeable improvement in memory recall and verbal fluency; adjust dosing as needed
- Week 2-3: Enhanced learning capacity and sustained attention; mood stabilization effects may emerge
- Week 4-6: Peak cognitive benefits with improved stress resilience and mental stamina
- Week 6-8: Sustained effects; consider cycle break to maintain sensitivity
- Post-cycle: Gradual return to baseline over 1-2 weeks; some users report lasting improvements
Side Effects & Safety
- Start with 10mg once daily to assess individual response before increasing dose
- Always pair with a choline source (Alpha-GPC or CDP-Choline) to prevent headaches
- Avoid evening dosing as cognitive stimulation may interfere with sleep
- Do not combine with other strong cholinergic or glutamatergic compounds without caution
- Not recommended for pregnant or breastfeeding women due to lack of safety data
- Individuals with liver conditions should consult healthcare provider before use
References
Neuroprotection in Alzheimer's Model (2015)
Omberacetam demonstrated significant neuroprotective effects against Alzheimer's disease-related pathology, attenuating apoptosis and reducing tau hyperphosphorylation in human neuronal cells exposed to amyloid-beta toxicity.
Neurotrophic Factor Expression (2009)
Acute administration elevated BDNF mRNA levels by up to 1.4-fold and NGF mRNA by 1.3-fold in hippocampus within 3 hours post-injection, demonstrating rapid neurotrophic activity supporting neuroplasticity.
Human Cognitive Enhancement Trial (2008)
Patients with cognitive impairment from vascular cerebral damage or post-traumatic injury showed universal improvement on measured parameters. MMSE scores increased from 26 to 29 in the Omberacetam group with 1.8-fold fewer side effects compared to piracetam.
Quick Start Guide
Community Poll
Question 1 of 10
What is your experience with this compound?
Poll Results
Loading results...
Community Insights
Self-reported by PepPedia users. Not clinical evidence. Health changes reflect all users, including those taking multiple compounds.
Was this helpful?
Your feedback helps us improve PepPedia